Asia Pacific Radiopharmaceuticals Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
USD
1.76 Billion
USD
2.73 Billion
2023
2031
 Período de pronóstico |
2024 –2031 |
 Tamaño del mercado (año base) |
USD 1.76 Billion |
 Tamaño del mercado (año de pronóstico) |
USD 2.73 Billion |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
Segmentación del mercado de radiofármacos de Asia y el Pacífico, por tipo (radiofármacos de diagnóstico y radiofármacos terapéuticos), aplicación (diagnóstico y terapéutico), tipo de fármaco (genéricos y de marca), fuente (reactores nucleares, ciclotrones y otros), usuario final (hospitales, centros de diagnóstico, institutos de investigación del cáncer, centros quirúrgicos ambulatorios y otros): tendencias de la industria y pronóstico hasta 2031.
Análisis y tamaño del mercado de radiofármacos de Asia y el Pacífico
El mercado de implantes corneales de Asia y el Pacífico está impulsado por varios factores, entre ellos la creciente prevalencia de enfermedades de la córnea, el envejecimiento de la población, los avances tecnológicos, la creciente demanda de procedimientos mínimamente invasivos, la creciente concienciación sobre el trasplante de córnea, las iniciativas y la financiación gubernamentales, la creciente adopción de lentes híbridas y tóricas, la creciente popularidad de los procedimientos de reticulación, la expansión de las indicaciones para implantes corneales y un panorama competitivo que fomenta la innovación. Estos factores impulsan colectivamente la demanda de implantes corneales, en particular en los países desarrollados, ya que los pacientes buscan tratamientos eficaces para trastornos y afecciones de la visión como el queratocono, la distrofia de Fuchs y la queratopatía ampollosa pseudofáquica.
Data Bridge Market Research analiza que se espera que el mercado de radiofármacos de Asia-Pacífico alcance los USD 2,73 mil millones para 2031 desde USD 1,76 mil millones en 2023, creciendo con una CAGR del 5,7% durante el período de pronóstico de 2024 a 2031.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2024 a 2031 |
|
Año base |
2023 |
|
Años históricos |
2022 (Personalizable 2016-2021) |
|
Unidades cuantitativas |
Ingresos en miles de millones de USD |
|
Segmentos cubiertos |
Tipo (radiofármacos de diagnóstico y radiofármacos terapéuticos), aplicación (diagnóstica y terapéutica), tipo de fármaco (genéricos y de marca), origen (reactores nucleares, ciclotrones y otros), usuario final (hospitales, centros de diagnóstico, institutos de investigación del cáncer, centros de cirugía ambulatoria y otros) |
|
Países cubiertos |
China, Japón, Australia, Corea del Sur, Singapur, India, Indonesia, Filipinas, Malasia, Vietnam y el resto de Asia-Pacífico. |
|
Actores del mercado cubiertos |
Cardinal Health, Advanced Accelerator Applications, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma (una empresa de Jubilant Pharma), Ansto, Eli Lilly And Company, Bayer AG, Siemens Healthcare Gmbh (China), Isotope & Radiation Corporation, Bracco, NTP, Eckert & Ziegler, Eczacıbaşı-Monrol, IBA Worldwide, BWX Technologies Inc, Isotope JSC y Sterigenics US LLC, entre otros. |
Definición de mercado
Un radiofármaco contiene una sustancia radiactiva asociada a uno o más ingredientes y que está destinada a diagnosticar, estadificar una enfermedad, monitorear el tratamiento o brindar terapia. Los radiofármacos incluyen un grupo de agentes radiactivos utilizados para intervenciones diagnósticas o terapéuticas. Los radiofármacos son los productos farmacéuticos que incorporan un radionúclido. La mayoría de los radiofármacos son una combinación de un nucleido o radionúclido radiactivo y una molécula o fármaco biológicamente activo que actúa como portador y determina la localización y biodistribución.
Dinámica del mercado de radiofármacos en Asia y el Pacífico
En esta sección se aborda la comprensión de los factores impulsores, las ventajas, las oportunidades, las limitaciones y los desafíos del mercado. Todo esto se analiza en detalle a continuación:
Conductores
La creciente demanda de radiofármacos para el diagnóstico y el uso clínico
Los radiofármacos se han vuelto esenciales para ayudar a diagnosticar órganos y tratar trastornos patológicos. Se utilizan en el diagnóstico por imagen y la radioterapia. Los radiofármacos de diagnóstico no tienen efectos farmacológicos y su administración tampoco se considera asociada con efectos secundarios clínicos relevantes.
El número de radiofármacos en uso clínico está aumentando rápidamente, lo que permite a la comunidad médica un mejor acceso a información detallada sobre las características de los diferentes tipos de tumores. Los radionúclidos también están ganando importancia al proporcionar tratamiento paliativo y curativo para un número cada vez mayor de enfermedades malignas.
Por ejemplo,
- En febrero de 2024, según el artículo publicado por la Agencia Internacional de Energía Atómica, los radiofármacos se utilizan en el diagnóstico mediante la administración de compuestos radiactivos que emiten fotones gamma, que penetran en el cuerpo y son detectados por cámaras externas para producir imágenes de los tejidos u órganos objetivo. Estas imágenes ayudan a detectar tumores, evaluar la función de los órganos y diagnosticar afecciones como el cáncer y las enfermedades cardiovasculares. A diferencia de los rayos X, a menudo se requiere un período de espera para que el radiofármaco llegue a su objetivo, lo que permite obtener imágenes precisas.
La creciente necesidad de productos farmacéuticos en diversas áreas terapéuticas
El aumento de casos de nuevas enfermedades en todo el mundo es una preocupación importante para los proveedores de atención médica. Las empresas farmacéuticas y biofarmacéuticas se esfuerzan día a día para abordar el desafío asociado con diversas enfermedades. El creciente interés de los actores del mercado dispuestos a proporcionar una amplia gama de productos radiofarmacéuticos para su uso en una formulación diferente impulsa el crecimiento del mercado.
La creciente prevalencia de enfermedades relacionadas con la edad, el tipo de población, la herencia genética y la propagación mundial de enfermedades infecciosas crónicas es el principal factor que explica la creciente demanda de productos radiofarmacéuticos. Se han descrito para el diagnóstico de enfermedades inflamatorias crónicas y se han radiomarcado varios péptidos, ligandos de receptores y anticuerpos monoclonales que permiten la visualización in vivo de procesos inflamatorios a nivel celular y molecular.
Por ejemplo,
- En febrero de 2019, según un artículo del NCBI, una serie de desarrollos recientes sugieren que la terapia con radiofármacos está lista para surgir como una modalidad terapéutica importante y ampliamente reconocida que tiene la capacidad de administrar radiación citotóxica a las células tumorales sin causar una toxicidad prohibitiva en el tejido normal.
Oportunidad
El aumento del gasto en investigación y desarrollo de radiofármacos
Los avances tecnológicos incluyen la mejora de la estabilidad y la potencia de los productos farmacéuticos tradicionales. Las empresas biotecnológicas y farmacéuticas invierten continuamente en investigación y desarrollo para ofrecer servicios innovadores de diagnóstico y medicamentos a los clientes y mejorar su presencia en el mercado. Los radiofármacos desempeñan un papel dinámico en el desarrollo clínico. Si bien la industria del diagnóstico se encuentra en un estado constante de fluctuación debido a la implementación de nuevas tecnologías en el mercado, las industrias farmacéutica y biotecnológica siguen aumentando debido a la mayor inversión en empresas de radiofármacos junto con las fusiones y adquisiciones y la adopción de innovaciones en tecnologías de imágenes para respaldar los ensayos clínicos de diversas enfermedades .
Restricción/Desafío
- Riesgos potenciales asociados a los radiofármacos
La exposición crónica por inhalación al uranio y al radón en humanos se ha relacionado con efectos respiratorios, como enfermedades pulmonares crónicas, mientras que la exposición al radio ha provocado leucopenia aguda, anemia, necrosis de la mandíbula y otros efectos. El radio, un elemento radiactivo, parece una molécula de calcio que se incorpora a las zonas del cuerpo donde la renovación ósea es alta, como las zonas de los órganos donde crece el cáncer. Aparte de esto, también existen algunos riesgos de procedimiento asociados con los radiofármacos.
Acontecimientos recientes
• En octubre de 2022, Forbes reconoció a Cardinal Health como una de las mejores empresas grandes empleadoras de Estados Unidos en 2022 a través de una encuesta independiente realizada a aproximadamente 60.000 empleados estadounidenses que trabajan para empresas estadounidenses. La empresa cree que esto los inspirará y motivará a sus empleados.
- En diciembre de 2022, Novartis recibió la aprobación de la Comisión Europea para Pluvicto como la primera terapia dirigida con radioligandos para el tratamiento del cáncer de próstata. La empresa cree que esto ayudará a impulsar una amplia gama de terapias con radioligandos para tratar el cáncer.
- En agosto de 2024, Lantheus Holdings, Inc. (“Lantheus”), la empresa líder centrada en radiofármacos comprometida a permitir que los médicos detecten, combatan y sigan las enfermedades para ofrecer mejores resultados a los pacientes, anunció hoy que Oliver Sartor, MD, director de ensayos radiofarmacéuticos y profesor de oncología médica en la Clínica Mayo en Rochester, Minnesota, realizará una presentación oral, que incluirá datos clínicos adicionales de la lectura inicial de PNT2002 de diciembre de 2023, durante la Reunión Anual de la Sociedad Europea de Oncología Médica (ESMO) en Barcelona el domingo 15 de septiembre de 2024.
- En julio de 2024, ANSTO y la Universidad de Wollongong desarrollaron un dispositivo Quad-MOSFET para el control de calidad en tiempo real en la terapia de captura de neutrones de boro. Esta innovadora herramienta mejora la precisión al distinguir los niveles de energía de los neutrones, lo que mejora la seguridad y la eficacia del tratamiento del cáncer.
Alcance del mercado de radiofármacos en Asia y el Pacífico
El mercado de radiofármacos de Asia-Pacífico está segmentado en ocho segmentos notables según el tipo, la aplicación, el tipo de fármaco, la fuente y el usuario final. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y las diferencias en sus mercados objetivo.
Tipo
- Radiofármacos de diagnóstico
- Radiofármacos terapéuticos
Según el tipo, el mercado de radiofármacos de Asia y el Pacífico está segmentado en radiofármacos de diagnóstico y radiofármacos terapéuticos.
Solicitud
- Diagnóstico
- Terapéutico
Sobre la base de la aplicación, el mercado de radiofármacos de Asia y el Pacífico está segmentado en diagnóstico y terapéutico.
Tipo de droga
- De marca
- Genéricos
Según el tipo de medicamento, el mercado de radiofármacos de Asia y el Pacífico está segmentado en genéricos y de marca.
Fuente
- Reactores nucleares
- Ciclotrones
- Otros
Según la fuente, el mercado de radiofármacos de Asia y el Pacífico está segmentado en reactores nucleares, ciclotrones y otros.
Usuario final
- Hospitales
- Centros de diagnóstico
- Institutos de investigación del cáncer
- Centros de cirugía ambulatoria
- Otros
Sobre la base del usuario final, el mercado de radiofármacos de Asia-Pacífico está segmentado en hospitales, centros de diagnóstico, institutos de investigación del cáncer, centros quirúrgicos ambulatorios y otros.
Análisis y perspectivas regionales del mercado de radiofármacos de Asia y el Pacífico
Se analiza el mercado de radiofármacos de Asia y el Pacífico y se proporcionan información y tendencias sobre el tamaño del mercado según el tipo, la aplicación, el tipo de fármaco, la fuente y el usuario final.
Los países cubiertos en este informe de mercado son China, Japón, Australia, Corea del Sur, Singapur, India, Indonesia, Filipinas, Malasia, Vietnam y el resto de Asia-Pacífico.
Se espera que China domine el mercado de Asia y el Pacífico debido a su gran población, el aumento del gasto en atención médica, la expansión de la industria farmacéutica, la creciente conciencia de los consumidores y la demanda de tratamientos, junto con una infraestructura de atención médica en desarrollo y una prevalencia creciente.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor ascendente y descendente, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia-Pacífico y sus desafíos enfrentados debido a la gran o escasa competencia de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de los radiofármacos en Asia y el Pacífico
El panorama competitivo del mercado de radiofármacos de Asia-Pacífico proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia regional, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado de radiofármacos de Asia-Pacífico.
Algunos de los principales actores que operan en el mercado de radiofármacos de Asia-Pacífico son Cardinal Health, Advanced Accelerator Applications, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma, (A Jubilant Pharma Company), Ansto, Eli Lilly And Company, Bayer AG, Siemens Healthcare Gmbh, China, lsotope & Radiation Corporation, Bracco, NTP, Eckert & Ziegler, Eczacıbaşı-Monrol, IBA Worldwide, BWX Technologies. Inc, Isotope JSC, Sterigenics US, LLC entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET TESTING TYPE COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
6.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
6.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
6.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
6.3 OPPORTUNITIES
6.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
6.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 BRANDED
7.3 GENERICS
8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 ONCOLOGY
9.2.2 CARDIOLOGY
9.2.3 NEUROLOGY
9.2.4 BONE SCANS
9.2.5 THYROID APPLICATIONS
9.2.6 PULMONARY SCANS
9.2.7 OTHERS
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
10.4 OTHERS
11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC
11.2.2 PRIVATE
11.2.2.1 DIAGNOSTIC CENTERS
11.2.2.2 CANCER RESEARCH INSTITUTES
11.2.2.3 AMBULATORY SURGICAL CENTERS
11.2.2.4 OTHERS
12 APAC RADIOPHARMACEUTICALS MARKET, BY COUNTRY
12.1 ASIA-PACIFIC
13 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENT
15.5 GE HEALTHCARE
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ANSTO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT UPDATES
15.7 BAYER AG
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 BRACCO
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BWX TECHNOLOGIES. INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 CHINA ISOTOPE & RADIATION CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ELI LILLY AND COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 ECKERT & ZIEGLER
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 GLOBAL MEDICAL SOLUTIONS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 ECZACIBAŞI-MONROL
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 IBA WORLDWIDE
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 ISOTOPE JSC
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 MALLINCKRODT PHARMACEUTICALS
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT UPDATES
15.19 NTP
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 STERIGENICS U.S., LLC – A SOTERA HEALTH COMPANY
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tablas
TABLE 1 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 6 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 7 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 9 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 10 ASIA-PACIFIC THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 13 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 14 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 16 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 17 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 19 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 27 CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 CHINA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 31 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 32 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 34 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 35 CHINA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 38 100
TABLE 39 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 40 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 41 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 42 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 43 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 45 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 46 CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 47 CHINA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 CHINA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 CHINA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 50 CHINA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 51 CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 52 CHINA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 57 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 58 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 60 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 61 AUSTRALIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 64 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 65 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 67 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 68 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 70 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 71 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 72 AUSTRALIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 AUSTRALIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 75 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 76 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 AUSTRALIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 82 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 83 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 85 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 86 JAPAN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 89 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 90 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 92 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 93 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 95 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 96 JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 97 JAPAN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 JAPAN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 JAPAN RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 100 JAPAN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 102 JAPAN HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 SOUTH KOREA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 107 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 108 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 110 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 111 SOUTH KOREA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 114 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 115 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 117 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 118 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 120 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 121 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 122 SOUTH KOREA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 SOUTH KOREA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 125 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 126 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 127 SOUTH KOREA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 SINGAPORE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 132 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 133 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 135 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 136 SINGAPORE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 139 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 140 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 141 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 142 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 143 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 145 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 146 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 147 SINGAPORE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 SINGAPORE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 SINGAPORE HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 153 INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 INDIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 157 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 158 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 160 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 161 INDIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 164 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 165 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 167 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 168 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 170 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 171 INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 172 INDIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 INDIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 INDIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 175 INDIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 176 INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 INDIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 182 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 183 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 185 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 186 INDONESIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 189 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 190 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 192 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 193 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 195 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 196 INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 197 INDONESIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 INDONESIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 199 INDONESIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 200 INDONESIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 201 INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 202 INDONESIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 PHILIPPINES DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 207 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 208 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 210 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 211 PHILIPPINES THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 213 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 214 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 215 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 217 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 218 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 220 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 221 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 222 PHILIPPINES DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 225 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 227 PHILIPPINES HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 THAILAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 232 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 233 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 235 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 236 THAILAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 239 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 240 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 242 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 243 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 245 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 246 THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 247 THAILAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 THAILAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 THAILAND RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 250 THAILAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 251 THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 THAILAND HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 257 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 258 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 260 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 261 MALAYSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 264 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 265 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 267 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 268 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 269 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 270 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 271 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 272 MALAYSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 MALAYSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 274 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 275 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 276 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 277 MALAYSIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 VIETNAM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 VIETNAM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 282 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 283 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 285 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 286 VIETNAM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 287 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 289 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 290 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 292 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 293 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 294 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 295 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 296 VIETNAM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 297 VIETNAM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 298 VIETNAM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 299 VIETNAM RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 300 VIETNAM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 301 VIETNAM RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 302 VIETNAM HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET:
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 15 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2023
FIGURE 18 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 19 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023
FIGURE 22 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023
FIGURE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 27 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 28 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023
FIGURE 30 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2024-2031 (USD MILLION)
FIGURE 31 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2024-2031)
FIGURE 32 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2023
FIGURE 34 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 35 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 36 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 APAC RADIOPHARMACEUTICALS MARKET BY SNAPSHOT
FIGURE 38 AISA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2023 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
